The causes and consequences of HIV evolution

Nature Reviews Genetics

Volumn 5, Issue 1, 2004, Pages 52-61

  Rambaut, Andrew ^a   Posada, David ^b   Crandall, Keith A ^c   Holmes, Edward C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF VIGO   (Spain)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; EVOLUTION; GENE MUTATION; GENETIC RECOMBINATION; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENTIVIRINAE; MULTIDRUG RESISTANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYLOGENY; PRIMATE; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INFECTION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; DRUG RESISTANCE, MULTIPLE, VIRAL; EVOLUTION; HISTORY, 20TH CENTURY; HIV; HUMANS; LENTIVIRUS; PHYLOGENY; PRIMATES; RECOMBINATION, GENETIC; VARIATION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LENTIVIRUS; PRIMATES; RNA VIRUSES;

EID: 0347989161     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1246     Document Type: Review

References (105)

1. UNAIDS. AIDS Epidemic Update 2002, « http://www.unaids.org/worldaidsday/2002/press/Epiupdate. HtmlReport» (2002).
2. Hahn, B. H., Shaw, G. M., de Cock, K. M. & Sharp, P. M. AIDS as a zoonosis: scientific and public health implications. Science 287, 607-614 (2000). Important review of the origin of HIV-1 and HIV-2. Clearly shows that AIDS is a zoonotic disease with its origins in the primate lentiviruses.
3. Gao, F. et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436-441 (1999).
4. Santiago, M. L. et al. SIVcpz in wild chimpanzees. Science 295, 465-465 (2002).
5. Gao, F. et al. Human infection by genetically diverse SIVsm-related HIV-2 in West Africa. Nature 358, 495-499 (1992).
6. Sharp, P. M. et al. The origins of acquired immune deficiency syndrome viruses: where and when. Phil. Trans. Roy. Lond. B 356, 867-876 (2001).
7. Salemi, M. et al. Mosaic genomes of the six major primate lentiviruses lineages revealed by phylogenetic analysis. J. Virol. 77, 7202-7213 (2003).
8. Bailes, E. et al. Hybrid origin of SIV in chimpanzees. Science 300, 1713 (2003). Recent sequence analysis paper showing that chimpanzee SIVcpz has a hybrid origin, with two monkey SIVs acting as 'parental' strains.
9. Allan, J. S. et al. Species-specific diversity among simian immunodeficiency viruses from African green monkeys. J. Virol. 65, 2816-2828 (1991).
10. Beer, B. E. et al. Simian immunodefiency virus (SIV) from sun-tailed monkeys (Ceropithecus solatus): evidence for host-dependent evolution of SIV within the C. lhoesti superspecies. J. Virol. 73, 7734-7744 (1999).
11. Bibollet-Ruche, F. et al. Simian immunodeficiency virus infection in a patas monkey (Erythrocebus patas): evidence for cross-species transmission from African green monkeys (Cercopithecus aethiops sabaeus) in the wild. J. Virol. 77, 773-781 (1996).
12. Courgnaud, V. et al. Partial molecular characterization of two simian immunodeficiency virus (SIV) from African colobids: SIVwrc from western red colobus (Piliocolobus badius) and SIVolc from olive colobus (Procolobus verus). J. Virol. 77, 744-748 (2003).
13. Charleston, M. A. & Robertson, D. L. Preferential host switching by primate lentiviruses can account for phylogenetic similarity with the primate phylogeny. Syst. Biol. 51, 528-535 (2002).
14. Sharp, P. M. et al. Origins and evolution of AIDS viruses: estimating the timescale. Biochem. Soc. Trans. 28, 275-282 (2000).
15. Müller-Trutwin, M. C. et al. The evolutionary rate of nonpathogenic simian immunodeficiency virus (SIVagm) is in agreement with a rapid and continuous replication in vivo. Virology 223, 89-102 (1996).
16. Rey-Cuillé, M. A. et al. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J. Virol. 72, 3872-3886 (1998).
17. Korber, B. et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789-1796 (2000). High-profile paper that provides a timescale for the origin and evolution of HIV-1.
18. Salemi, M. et al. Dating the radiation of HIV-1 group M in 1930s using a new method to uncover clock-like molecular evolution. FASEB J. 15, 276-278 (2000).
19. Yusim, K. et al. Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution. Phil. Trans. R. Soc. Lond. B 356, 855-866 (2001).
20. Lemey, P. et al. Tracing the origin and history of the HIV-2 epidemic. Proc. Natl Acad. Sci. USA 100, 6588-6592 (2003).
21. Schierup, M. H. & Hein, J. Recombination and the molecular clock. Mol. Biol. Evol. 17, 1578-1579 (2000).
22. Worobey, M. A novel approach to detecting and measuring recombination: new insights into evolution in viruses, bacteria, and mitochondria. Mol. Biol. Evol. 18, 1425-1434 (2001).
23. Zhu, T. F. et al. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 391, 594-597 (1998).
24. Peeters, M. et al. Risk to human health from a plethora of Simian immunodeficiency viruses in primate bushmeat. Emerg. Infect. Dis. 8, 451-457 (2002).
25. Vidal, N. et al. Unprecedented degree of HIV-1 group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J. Virol. 74, 10498-10507 (2000).
26. Rambaut, A., Robertson, D. L., Pybus, O. G., Peeters, M. & Holmes, E. C. Phylogeny and the origin of HIV-1. Nature 410, 1047-1048 (2001). Shows how the subtype structure of the tree for the HIV-1 M group is produced by a combination of incomplete sampling and local founder effects.
27. Robbins, K. E. et al. US human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains. J. Virol. 77, 6359-6366 (2003).
28. Smith, U. R., Kuiken, C. & Korber, B. T. Recent evolutionary history of human immunodeficiency type 1 subtype B-response. J. Mol. Evol. 56, 643-644 (2003).
29. Holmes, E. C., Zhang, L. Q., Simmonds, P., Ludlam, C. A. & Leigh Brown, A. J. Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. Proc. Natl Acad. Sci. Sol. USA 89, 4835-4839 (1992).
30. Preston, B. D., Poiesz, B. J. & Loeb, L. A. Fidelity of HIV-1 reverse transcriptase. Science 242, 1169-1171 (1988).
31. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586 (1996). Presents an analysis that shows the remarkable replicatory dynamics of HIV.
32. Frost, S. D. W., Dumaurier, M. J., Wain-Hobson, S. & Leigh Brown, A. J. Genetic drift and within-host metapopulation dynamics of HIV-1 infection. Proc. Natl Acad. Sci. USA 98, 6975-6980 (2001).
33. Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144-4149 (2003).
34. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
35. Ross, H. A. & Rodrigo, A. G. Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J. Virol. 76, 11715-11720 (2002).
36. Kelleher, A. D. et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27 restricted CTL responses. J. Exp. Med. 193, 375-385 (2001).
37. Ogg, G. S. et al. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103-2106 (1998).
38. Phillips, R. E. et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453-459 (1991).
39. Yusim, K. et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J. Virol. 76, 8757-8768 (2002).
40. Allen, T. M. et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407, 386-390 (2000).
41. O'Connor, D. H. et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nature Med. 8, 493-499 (2002).
42. Barouch, D. H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339 (2002).
43. Bonhoeffer, S., Holmes, E. C. & Nowak, M. A. Causes of HIV diversity. Nature 376, 125 (1995).
44. Zanotto, P. M. D. A., Kallas, E. G., de Souza, R. F. & Holmes, E. C. Genealogical evidence for positive selection in the nef gene of HIV-1. Genetics 153, 1077-1089 (1999).
45. Williamson, S. Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression. Mol. Biol. Evol. 20, 1318-1325 (2003). Important paper that presents an analysis of the rate of adaptive evolution in a large number of HIV patients and how this relates to disease progression.
46. Nowak, M. A. et al. Antigenic diversity threshold and the development of AIDS. Science 254, 963-969 (1991).
47. Markham, R. B. et al. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc. Natl Acad. Sci. USA 95, 12568-12573 (1998).
48. Shankarappa, R. et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73, 10489-10502 (1999). An extensive analysis of the dynamics of intra-host HIV evolution in a multi-patient study.
49. Wolinksy, S. M. et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272, 537-542 (1996).
50. Anisimova, M., Nielsen, R. & Yang, Z. Effect of recombination on the accuracy of the likelihood ratio method for detecting positive selection at amino acid sites. Genetics 164 1229-1236 (2003).
51. Shriner, D., Nickle, D. C., Jensen, M. A. & Mullins, J. I. Potential impact of recombination on sitewise approaches for detecting positive natural selection. Genet. Res. 81, 115-121 (2003).
52. Cheng-Mayer, C., Seto, D., Tateno, M. & Levy, J. A. Biological features of HIV-1 that correlate with virulence in the host. Science 240, 80-82 (1988).
53. Bjorndal, A. et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71, 7478-7487 (1997).
54. Zhang, L. Q. et al. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J. Virol. 72, 9301-9312 (1998).
55. Peeters, M. et al. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J. Acq. Imm. Def. Syn. Human Retro. 20, 115-121 (1999).
56. Ball, S. C. et al. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77, 1021-1038 (2003).
57. Delwart, E. et al. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 16, 189-195 (2002).
58. Zhu, T. F. et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 261, 1179-1181 (1993).
59. Dickover, R. E., Garratty, E. M., Plaeger, S. & Bryson, Y. J. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J. Virol. 75, 2194-2203 (2001).
60. Wolinksy, S. M. et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255, 1134-1137 (1992).
61. Verhofstede, C. et al. Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J. Virol. 77, 3050-3057 (2003).
62. Goulder, P. J. R. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med. 3, 212-217 (1997).
63. Moore, C. B. et al. Evidence for HIV-1 adaptation to HLA-restricted immune responses at the population level. Science 296, 1439-1443 (2002). Extensive study that shows how HIV-1 adapts to HLA haplotypes at the intra-host level. However, the paper does not consider whether intra-host 'escape' mutants are transmitted among hosts.
64. Goulder, P. J. R. et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412, 334-337 (2001).
65. Zhuang, J. et al. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J. Virol. 76, 11273-11282 (2002). Recent paper that shows the extremely high rate of recombination in HIV.
66. Jung, A. et al. Multiply infected spleen cells in HIV patients. Nature 418, 144 (2002).
67. Jost, S. et al. A patient with HIV-1 superinfection. N. Engl. J. Med. 347, 731-736 (2002).
68. Koelsch, K. K. et al. Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS 17, F11-6 (2003).
69. Takehisa, J. et al. Human immunodeficiency virus type 1 intergroup (M/O) recombination in cameroon. J. Virol. 73, 6810-6820 (1999).
70. Robertson, D. L., Sharp, P. M., McCutchan, F. E. & Hahn, B. H. Recombination in HIV-1. Nature 374, 124-126 (1995).
71. Crandall, K. A. & Templeton, A. R. in The Evolution of HIV (ed. Crandall, K. A.) 153-176 (The Johns Hopkins University Press, Baltimore, 1999).
72. Pandrea, I. et al. Analysis of partial pot and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon. AIDS Res. Hum. Retroviruses 18, 1103-1116 (2002).
73. McVean, G., Awadalla, P. & Fearnhead, P. A coalescent-based method for detecting and estimating recombination from gene sequences. Genetics 160, 1231-1241 (2002).
74. Posada, D. & Crandall, K. A. The effect of recombination on the accuracy of phylogeny estimation. J. Mol. Evol. 54, 396-402 (2002).
75. Schierup, M. H. & Forsberg, R. in Proceedings of the conference: Origin of HIV and emerging persistent viruses (Accademia Nazionale dei Lincei, Rome, 2003).
76. Posada, D. & Crandall, K. A. Intraspecific gene genealogies: trees grafting into networks. Trends Ecol. Evol. 16, 37-45 (2001).
77. Wain-Hobson, S., Renoux-Elbe, C., Vartanian, J. P. & Meyerhans, A. Network analysis of human and simian immunodeficiency virus sequence sets reveals massive recombination resulting in shorter pathways. J. Gen. Virol. 84, 885-895 (2003).
78. Liu, S. L. et al. Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J. Virol. 76, 10674-10684 (2002).
79. Nájera, R., Delgado, E., Pérez-Alvarez, L. & Thomson, M. M. Genetic recombination and its role in the development of the HIV-1 pandemic. AIDS 16, S3-16 (2002).
80. Kellam, P. & Larder, B. A. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J. Virol. 69, 669-674 (1995).
81. Morris, A. et al. Mosaic structure of the human immunodeficiency virus type 1 genome infecting lymphoid cells and the brain: evidence for frequent in vivo recombination events in the evolution of regional populations. J. Virol. 73, 8720-8731 (1999).
82. Wain-Hobson, S. Down or out in blood and lymph? Nature 387, 123-124 (1997).
83. Perelson, A. S. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
84. Cohen, O. J. & Fauci, A. S. Transmission of multidrug-resistant human immunodeficiency virus - the wake-up call. N. Engl. J. Med. 339, 341-343 (1998).
85. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278, 1295-1300 (1997).
86. Blankson, J. N., Persaud, D. & Siliciano, R. F. The challenge of viral reservoirs in HIV-1 infection. Ann. Rev. Med. 53, 557-593 (2002).
87. Smith, B. A. et al. Persistence of infectious HIV on follicular dendritic cells. J. Immunol. 166, 690-696 (2001).
88. Igarashi, T. et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl Acad. Sci. USA 98, 658-663 (2001).
89. Clements, J. et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J. Infect. Dis. 166, 905-913 (2002).
90. Molla, A. et al. Ordered accumulation of mutations in HIV protease confer resistance to ritonavir. Nature Med. 2, 760-766 (1996).
91. Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
92. Chun, T.-W., Davey, R. T., Engel, D., Lane, H. C. & Fauci, A. S. AIDS: re-emergence of HIV after stopping therapy. Nature 401, 874-875 (1999). Important paper that explores the development of drug resistance in HIV.
93. Martinez-Picado, J. et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl Acad. Sci. USA 97, 10948-10953 (2000).
94. Ribeiro, R. M. & Bonhoeffer, S. Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl Acad. Sci. USA 97, 7681-7686 (2000).
95. Simon, V. et al. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J. Virol. 77, 7736-7745 (2003).
96. Pitisuttithum, P. et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J. Infect. Dis. 188, 219-227 (2003).
97. Back, N. K. et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15, 4040-4049 (1996).
98. Baba, T. W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Med. 6, 200-206 (2000).
99. Greenough, T. C., Sullivan, J. L. & Desrosiers, R. C. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N. Engl. J. Med. 340, 236-237 (1999).
100. Berman, P. Preliminary results of VAX004: The first large scale field trial of an HIV vaccine in Keystone Conference: HIV Vaccine (Banf, CA, 2003).
101. Gaschen, B. et al. Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360 (2003).
102. Nickle, D. C. et al. Consensus and Ancestral State HIV Vaccines. Science 299, 1515-1518 (2003).
103. Barré-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983). Ground-breaking paper that reports the isolation of HIV for the first time.
104. Walker, P. R., Worobey, M., Rambaut, A., Holmes, E. C. & Pybus, O. G. Sexual transmission of HIV in Africa. Nature 422, 679 (2003).
105. Drummond, A. J., Pybus, O. G. & Rambaut, A. Inference of viral evolutionary rates from molecular sequences. Adv. Parasit. 54, 331-358 (2003). Review that describes the methods for estimating rates of evolution from virus sequences that have been sampled over time.